Interní Med. 2016; 18(2): 74-76 | DOI: 10.36290/int.2016.018

Statin associated muscle symptoms - literature review and our experience

MUDr.Ľubica Cibičková, Ph.D., doc.MUDr.David Karásek, Ph.D.
Fakultní nemocnice Olomouc, 3. interní klinika &ndash, nefrologická, revmatologická, endokrinologická

Muscle symptoms associated with statin therapy (statin associated muscle symptoms, SAMS) decreases patients’ adherence to this

effective therapy. SAMS are not specific muscle aches, which can but needen’t to be accompanied by elevation of creatinkinase.

Their occurrence differs depending on the type of performed study with statins. Older patients, females, patients with concomitant

medication, comorbidities, higher physical activity, alcohol intake and genetically predisposed patients are in higher risk

in developing SAMS. Although concrete mechanism leading to development of SAMS is not clear, consequences of SAMS are

clearly negative – lower compliance resulting in higher cardiovascular risk. We recommend to try various dosing and switching

from one statin to another one. Using coenzyme Q and vitamin D lacks serous data by now. In the end, we describe a short case

of a patient with SAMS after using several statins.

Keywords: statin, statin associated muscle symptoms, adherence

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cibičková Ľ, Karásek D. Statin associated muscle symptoms - literature review and our experience. Interní Med. 2016;18(2):74-76. doi: 10.36290/int.2016.018.
Download citation

References

  1. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014; 8(3 Suppl): 58-71. Go to original source...
  2. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015; 36(17): 1012-1022. Go to original source... Go to PubMed...
  3. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006; 119(5): 400-409. Go to original source... Go to PubMed...
  4. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010; 210(2): 337-343. Go to original source...
  5. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol. 2007; 99(4): 530-534. Go to original source...
  6. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002; 88(3): 229-233. Go to original source...
  7. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288(4): 462-467. Go to original source... Go to PubMed...
  8. McGinnis B, Olson KL, Magid D, Bayliss E, Korner EJ, Brand DW, Steiner JF. Factors related to adherence to statin therapy. Ann Pharmacother. 2007; 41(11): 1805-1811. Go to original source... Go to PubMed...
  9. Vodonos A, Ostapenko I, Toledano R, Henkin Y, Zahger D, Wolak T, Sherf M, Novack V. Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade? Eur J Intern Med. 2015; 26(4): 268-272. Go to original source...
  10. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006; 97(1): 61-67. Go to original source... Go to PubMed...
  11. Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Lip GY, Dragan S, Mikhailidis DP. Lipid and Blood Pressure Meta-analysis Collaboration Group. Mayo Clin Proc. 2015; 90(1): 24-34. Go to original source...
  12. Mergenhagen K, Ott M, Heckman K, Rubin LM, Kellick K. Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. Clin Ther 2014; 36(5): 770-777. Go to original source...
  13. Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012; 28(7): 1247-1252. Go to original source...
  14. Goláň L. Chyby a úskalí terapie statiny. Int med prax 2003(11): 552-553.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.